Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Viracta Therapeutics Inc VIRX

Healthcare Biotechnology
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated... see more

Recent & Breaking News (NDAQ:VIRX)

Sunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights

GlobeNewswire November 10, 2014

Sunesis to Present at Upcoming Investor Conferences

GlobeNewswire November 5, 2014

Sunesis to Host Conference Call on November 10th to Discuss Third Quarter 2014 Financial Results and Recent Highlights

GlobeNewswire November 3, 2014

Sunesis Announces Results From Pivotal Phase 3 VALOR Trial of Vosaroxin and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia

GlobeNewswire October 6, 2014

Sunesis to Present at the 2014 Morgan Stanley Global Healthcare Conference

GlobeNewswire September 4, 2014

Sunesis Pharmaceuticals Inc. (SNSS) Drops 5.47% on August 28

Equities.com August 28, 2014

Sunesis Pharmaceuticals Inc. (SNSS) Drops 6.65% on August 21

Equities.com August 21, 2014

Sunesis to Present at the 2014 Wedbush Life Sciences Management Access Conference

GlobeNewswire August 6, 2014

Sunesis Pharmaceuticals Reports Second Quarter 2014 Financial Results and Recent Highlights

GlobeNewswire August 5, 2014

Sunesis to Host Conference Call on August 5th to Discuss Second Quarter 2014 Financial Results and Recent Highlights

GlobeNewswire July 29, 2014

Sunesis Pharmaceuticals Announces European Medicines Agency Acceptance of Pediatric Investigation Plan for Qinprezo(TM) (Vosaroxin) for AML

GlobeNewswire July 9, 2014

Sunesis to Present at the 2014 Wells Fargo Healthcare Conference

GlobeNewswire June 11, 2014

Looking at the Latest in Immunotherapies

Equities.com June 5, 2014

Sunesis Announces Presentation of Positive Updated Results From Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS at ASCO 2014 Annual Meeting

GlobeNewswire June 2, 2014

Sunesis to Present at Upcoming Investor Conferences

GlobeNewswire May 14, 2014

Sunesis Pharmaceuticals Reports First Quarter 2014 Financial Results and Recent Highlights

GlobeNewswire May 7, 2014

Sunesis to Host Conference Call on May 7th to Discuss First Quarter 2014 Financial Results and Recent Highlights

GlobeNewswire April 30, 2014

Sunesis Announces MD Anderson Sponsored Study of Vosaroxin in AML and High-Risk MDS Poster to be Presented at ASCO 2014

GlobeNewswire April 22, 2014

Sunesis Announces Presentation of Positive Results From Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS

GlobeNewswire April 8, 2014

Sunesis Announces MD Anderson Sponsored Trial of Vosaroxin in AML and High-Risk MDS Poster to be Presented at AACR 2014

GlobeNewswire April 2, 2014